121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy

N. Peled, J. Mazieres, D.M. Kowalski,W-S. Lam, M.J. Hochmair, M. Majem,S.H. Kim,A. Calles Blanco, K. Cuppens, I.A. Casarini, O. Bylicki, B. Shim, J.B. Sørensen, M. Gilli, S.H. How, C. Schumann, C. Gonzalez Arenas, T. He, A. Samkari,S. Novello

Immuno-Oncology and Technology（2023）

引用 0|浏览0